EMD-65314

Single-particle
2.96 Å
EMD-65314
3D View Gallery
Deposition: 09/07/2025
Map released: 08/07/2026
Last modified: 08/07/2026
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-65314

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-9vt4 summary report (pdf.gz) Map-9vt4 FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

EBOV GP/BA2-VHH complex

EMD-65314

Single-particle
2.96 Å
EMD-65314
3D View Gallery
Deposition: 09/07/2025
Map released: 08/07/2026
Last modified: 08/07/2026
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Zaire ebolavirus, Ebola virus - Gabon (1994-1997), Vicugna pacos
Sample: EBOV GP/BA2 complex
Fitted models: 9vt4

Deposition Authors: Wang M, Gao Y, Jin T
A highly potent nanobody-based bispecific therapeutic provides broad-spectrum protection against ebolavirus.
Wang M, Zhang X, Li W, Yao Y, Li E, Zhang B, Zhou J, Liu S, Gao Y, Zhu Z, Zhu L, Liu M, Hu J, Peng C, Li F, Chen M, Liu H, Yao C, Shang Y, Yan F, Gong P, Jin T, Chiu S
(2026) Nat Commun , 17
PUBMED: 41839884
DOI: doi:10.1038/s41467-026-70464-6
ISSN: 2041-1723